Related Experiment Video

Updated: Apr 23, 2026

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

3.3K

Epidemiological trends in hypertrophic cardiomyopathy in adults-a Swedish nationwide registry study

Jonas Silverdal1,2, Tatara Delavaran3, J Gustav Smith2,3,4,5,6

  • 1Department of Medicine, Geriatrics and Emergency Care, Sahlgrenska University Hospital/Östra, Diagnosvägen 11, 416 50 Gothenburg,Sweden.

European Journal of Heart Failure
|April 22, 2026
PubMed

Insights

Hypertrophic cardiomyopathy (HCM) prevalence and incidence significantly increased in Sweden from 2003-2022, particularly for non-obstructive HCM in older adults. All-cause mortality halved, indicating improved prognosis and detection of milder cases.

Area of Science:

  • Cardiology
  • Epidemiology
  • Public Health

Background:

  • Hypertrophic cardiomyopathy (HCM) is a significant cause of heart failure and mortality.
  • Previous epidemiological data on HCM trends, especially differentiating obstructive (oHCM) and non-obstructive (nHCM) forms, are limited.
  • Understanding temporal changes in HCM incidence, prevalence, and outcomes is crucial for public health planning.

Purpose of the Study:

  • To investigate epidemiological shifts and mortality trends in hypertrophic cardiomyopathy (HCM) in Sweden.
  • To analyze changes in both obstructive (oHCM) and non-obstructive (nHCM) hypertrophic cardiomyopathy.
  • To assess outcomes across different age groups between 2003 and 2022.

Main Methods:

  • Utilized the Swedish National Patient Register for data on patients aged 17-85 diagnosed with HCM.
  • Categorized patients into obstructive (oHCM) and non-obstructive (nHCM) based on ICD-10 codes.
  • Calculated annual age- and sex-adjusted incidence, prevalence, and all-cause mortality, analyzing temporal trends with negative binomial regression.

Main Results:

  • Total HCM prevalence rose from 14 to 73 per 100,000 population.
  • Incidence increased from 5.1 to 9.3 per 100,000 person-years, driven by nHCM, especially in middle-aged and older adults.
  • All-cause mortality decreased significantly from 9.8% to 4.3%, with improved prognosis across all age groups.

Conclusions:

  • HCM prevalence and incidence have markedly increased, with nHCM showing the largest rise.
  • The observed trends are linked to increased detection of milder HCM phenotypes, particularly in older populations.
  • Significant reduction in all-cause mortality suggests improved management and outcomes for HCM patients.
Abstract

Keywords:
Cardiomyopathy, HypertrophicEpidemiologyIncidenceMortalityPrevalencePrognosis

More Related Videos

An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level06:02

An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level

Published on: November 2, 2020

6.6K
Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix10:21

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix

Published on: June 14, 2016

9.8K

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
795
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
809
Hypertension III: Clinical Manifestations and Diagnostic Studies01:30

Hypertension III: Clinical Manifestations and Diagnostic Studies

Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
755
Cellular Adaptation II: Hypertrophy01:26

Cellular Adaptation II: Hypertrophy

Hypertrophy is the increase in the size of individual cells, resulting in the enlargement of a tissue or organ. Unlike hyperplasia, which involves an increase in cell number, hypertrophy is characterized by an increase in cell volume. This process often occurs in response to higher functional demand or hormonal stimulation, leading to the production of more structural proteins and organelles, thereby enhancing the cells' work capacity.There are two primary types of hypertrophy:...
10
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
743
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies01:22

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
1.3K